, Volume 25, Supplement 2, pp 314–317 | Cite as

β-Blocker Heart Attack Trial

  • Curt D. Furberg
Section 7: Myocardial Infarction


The β- Blocker Heart Attack Trial (BHAT) was a National Heart, Lung, and Blood Institute-sponsored multicentre, double- blind controlled clinical trial designed to test whether the regular administration of propranolol to men and women who had experienced at least 1 documented myocardial infarction would result in a significant reduction in all-cause mortality during the follow-up period. A total of 3837 persons aged 30 to 69 years were randomised to either propranolol or placebo, 5 to 21 days after infarction. Based on serum drug level, the prescribed maintenance dose of propranolol was either 180 or 240 mg/day. BHAT was stopped 9 months ahead of schedule due to a beneficial drug effect. Total mortality during the average 25-month follow-up period was 7.2% in the propranolol group and 9.8% in the placebo group. This difference was explained by a reduction in coronary heart disease mortality, both in sudden (defined as death within 1 hour of onset of symptoms) and non-sudden death. Serious side effects were uncommon. Based on the BHAT results, the use of propranolol is recommended for at least 3 years in patients with a recent myocardial infarction, who have no contraindications to β- blockade.


Coronary Heart Disease Mortality Practolol Alprenolol Serum Drug Level Multicentre International Study 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andersen, M.P.; Bechsgaard, P.; Frederiksen, J.; Hansen, D.A.; Jürgensen, H.J.; Nielsen, B.; Pedersen, F.; Pedersen-Bjergaard, O. and Rasmussen, S.L.: Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2: 865–868 (1979).PubMedCrossRefGoogle Scholar
  2. β-Blocker Heart Attack Study Group: The β-Blocker Heart Attack Trial. Preliminary report. Journal of the American Medical Association 246: 2073–2074 (1981).CrossRefGoogle Scholar
  3. β-Blocker Heart Attack Study Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Morbidity results. Journal of the American Medical Association 247: 1707–1714 (1982).Google Scholar
  4. Furberg, C.D. and Friedewald, W.T.: The effects of chronic administration of beta-blockade on long term survival following myocardial infarction; in Braunwald (Ed.) Beta-Adrenergic Blockade, a New Era in Cardiovascular Medicine, pp. 171-178 (Excerpta Medica/Elsevier dy1978).Google Scholar
  5. Multicentre International Study: Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. British Medical Journal 3: 735–740 (1975).CrossRefGoogle Scholar
  6. Norwegian Multicentre Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine 304: 801–807 (1981).CrossRefGoogle Scholar
  7. O’Brien, P.C. and Fleming, T.R.: A multiple testing procedure for clinical trials. Biometrics 33: 549–556 (1979).CrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd (Inc. NSW) 1983

Authors and Affiliations

  • Curt D. Furberg
    • 1
  1. 1.Clinical Trials BranchNational Heart Lung and Blood InstituteBethesdaUSA

Personalised recommendations